Search clinical trials for: Sofosbuvir and Ledipasvir

Total 272132 results

Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Hepatitis C Virus Infection

Egypt
University Hospital, Akershus

Unknown

HCV Treatment in a Low-threshold Clinic (Prindsen)

Hepatitis C | Substance Use Disorders

Norway
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

Belgium, Austria, New Zealand, United Kingdom, Germany, Spain, Netherlands, France, Switzerland, Canada, Australia, Italy
Gilead Sciences

Terminated

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Hepatitis C Virus Infection

United States, Canada, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

Hepatitis C Virus Infection

United States, Taiwan, Belgium, Germany, Italy
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

HIV | Hepatitis C Virus

United States, New Zealand, Canada, Puerto Rico
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Completed

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (CHROME)

Cardiovascular Diseases | Hepatitis C | Hiv

United States
Kaiser Permanente
City of Hope National Medical Center

Withdrawn

Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.

Hematopoietic Stem Cell Transplantation

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Chronic HCV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Hepatitis C Virus Infection

Canada
Tanta University

Unknown

Sofosbuvir in Treatment of COVID 19

COVID

Egypt
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Estonia, Russian Federation
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Hepatitis C Virus Infection

United States
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Chang... and other collaborators

Withdrawn

DAA in the Risk of Recurrence After Curative Treatment of HCC

Hepatocellular Carcinoma
Janssen Sciences Ireland UC

Completed

A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Hepatitis C, Chronic

Belgium
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection

Hepatitis C Virus Infection

France, Austria, Germany, Italy
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Ottawa Hospital Research Institute
Gilead Sciences; CIHR Canadian HIV Trials Network

Completed

HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection (CTN289)

Hepatitis C, Chronic | Human Immunodeficiency Virus

Canada
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

HCV Infection

United States, France, Australia, Puerto Rico, Spain
ANRS, Emerging Infectious Diseases

Completed

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa (TAC)

HIV Infection | Hepatitis C

Cameroon, Côte D'Ivoire, Senegal
University Hospital, Geneva
Gastaldi Giacomo; Clément Sophie

Completed

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Insulin Resistance

Switzerland
Macfarlane Burnet Institute for Medical Research...
St Vincent's Hospital Melbourne

Unknown

The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (TAP)

Hepatitis C | Drug Abuse, Intravenous

Australia
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

HCV Infection

France
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

Hepatitis C Virus Infection

United States, New Zealand, Australia, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

HCV Infection

New Zealand, United States, Puerto Rico
National Liver Institute, Egypt

Completed

Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years

Hepatitis C, Chronic | Children, Only

Egypt
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Almaza Military Fever Hospital

Completed

Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment

Covid19

Egypt
University of California, San Francisco
National Institutes of Health Clinical Center (CC); Johns Hopkins University; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Completed

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (STOP-CO)

Hepatitis C | HIV | Cirrhosis

United States
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China
Valme University Hospital
Hospital Universitario de Canarias; Hospital Universitario Virgen Macarena; Hospital... and other collaborators

Unknown

Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients

Hepatitis C, Chronic | Human Immunodeficiency Virus

Spain
Gilead Sciences

Completed

Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Hepatitis C

Japan
Postgraduate Institute of Medical Education and...
Directorate of Health and Family Welfare, Punjab

Unknown

Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

Chronic Hepatitis c

India
National Institute of Allergy and Infectious Diseases...

Completed

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Hepatitis C | HIV

United States
Humanity and Health Research Centre
Beijing 302 Hospital; Nanfang Hospital of Southern Medical University

Completed

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (DASCO)

Chronic Hepatitis C Infection | Hepatitis B Reactivation | HBV Coinfection

China
Alexandria University

Completed

Effect of Hepatitis C Clearance on Insulin Resistance

Hepatitis C | Insulin Resistance

Egypt
Parc de Salut Mar

Completed

Impact of Antiviral Therapy on Gastroesophageal Varices.

Cirrhosis | Chronic Hepatitis C
Genuine Research Center, Egypt
MinaPharm Pharmaceuticals

Completed

A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Healthy

Egypt
Genuine Research Center, Egypt
Magic Pharma, Egypt

Completed

A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)

Healthy

Egypt
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Chronic Hepatitis C Virus

United States
Tehran University of Medical Sciences
Bakhtar Bioshimi Co

Completed

Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 (SL50)

Hepatitis C | Cirrhosis

Iran, Islamic Republic of
Gilead Sciences

Completed

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (Co-STARs)

HIV-1 Infection | HCV Infection

United States, Puerto Rico
Stanford University
Gilead Sciences

Completed

Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

PT-NANBH

United States

3

Subscribe